Drug Profile
XMP 391
Latest Information Update: 29 Jun 1999
Price :
$50
*
At a glance
- Originator XOMA
- Class Antifungals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 29 Jun 1999 Discontinued-Preclinical for Mycoses in USA (Unknown route)
- 20 Nov 1997 New profile
- 20 Nov 1997 Preclinical development for Mycoses in USA (Unknown route)